Tissue Regenix Group PLC Notice of Interim Results & Investor Presentation (2631X)

TIDMTRX

RNS Number : 2631X

Tissue Regenix Group PLC

27 August 2020

Tissue Regenix Group plc

Notice of Interim Results and Investor Presentation

Leeds, 27 August 2020 - Tissue Regenix Group (AIM:TRX) (the "Company") the regenerative medical devices company today gives notice that it will announce its unaudited interim results for the six months ending 30(th) June 2020, on Wednesday 2(nd) September 2020.

The Company is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base and will provide a live investor presentation relating to the 2020 interim results, via the Investor Meet Company platform, on Thursday 3(rd) September at 17:00.

This presentation is open to all existing and potential investors. Questions can be submitted prior to the event or any time during the live presentation via the "Ask a Question" function.

Investors can sign up to the Investor Meet Company for free and attend this presentation via the below link:

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Investors who have already registered to meet the Company, will be automatically invited to the meeting.

For more Information:

 
 Tissue Regenix Group plc                     Tel: 0330 430 3073 
  Caitlin Pearson Head of Communications 
------------------------------------------  --------------------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated               Tel: 0207 710 7600 
  Adviser and Broker) 
  Ben Maddison / Alex Price 
------------------------------------------  --------------------------------- 
 
 FTI Consulting                                      Tel: 0203 727 1000 
  Simon Conway / Victoria Foster Mitchell / 
  Mary Whittow

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAEPKADAEEAA

(END) Dow Jones Newswires

August 27, 2020 02:00 ET (06:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024